What Строфантин К treats: Main Uses and Benefits

The primary therapeutic role of Строфантин К involves providing support for a compromised heart, addressing specific conditions where enhanced cardiac performance and rate control may assist in stabilization. As a member of the cardiac glycoside class, it is commonly used to help with heart failure and certain irregular heartbeats.

---

Key Therapeutic Focus

This medication is considered relevant for managing conditions characterized by systemic imbalance, acute episodes of symptoms that create noticeable physiological strain, and specific cardiac arrhythmias like atrial fibrillation with a rapid ventricular response. It is often applied in clinical settings that involve acute or unstable symptom patterns. The benefit contributes to easing the overall symptom load associated with poor pumping power.

---

Quick Fact: Relief for Congestion and Physiological Strain

Feature	Description
Main Indication	Heart failure and specific irregular heart rhythms.
Symptom Focus	Addresses symptoms related to noticeable physiological strain and rapid heart rate.
Usage Context	Applied in clinical settings that involve acute or unstable symptom patterns for temporary cardiac support.
Patient Benefit	Contributes to easing the overall symptom load and assists with maintaining functional stability

Regulatory References

1. MedlinePlus Medical Encyclopedia overview on Cardiac Glycosides

This section outlines the official eligibility and non-eligibility criteria for using Строфантин К (Strophanthin K), as documented in governmental regulatory labeling.

Populations for Whom Use is Contraindicated (Must Not Be Used)

Criterion	Status
Hypersensitivity	Absolute contraindication to ouabain or cardiac glycosides.
Heart Block	Forbidden in second- or third-degree atrioventricular (AV) block unless a functioning pacemaker is present.
Cardiomyopathy	Contraindicated in obstructive hypertrophic cardiomyopathy.
Acute MI	Contraindicated during the acute phase of myocardial infarction.
Pregnancy	Contraindicated due to the risk of inducing uterine contractions.

Eligibility-Related Restrictions and Cautions

• Electrolyte Imbalances: Use is restricted until severe conditions like hypokalemia (low potassium) or hypercalcemia (high calcium) are fully corrected, as these critically increase the risk of toxicity.
• Renal Function: Patients with advanced renal failure require special caution and dosage adjustment due to impaired clearance and the risk of drug accumulation.
• Hypothyroidism: Requires caution and monitoring due to altered drug metabolism and excretion.
• Pediatric Population: Safety and efficacy are generally considered not established or associated with insufficient data in regulatory documents.

Connection to the Overall Eligibility Profile

The official eligibility profile for Строфантин К is strictly defined by major risks, establishing absolute prohibitions for patients with specific electrical and structural heart defects and women who are pregnant. For all other patients, the drug's use is subject to conditional constraints requiring careful assessment of electrolyte status, kidney function, and other comorbidities, as detailed in the official prescribing information.

Interactions with other medicines and products

The official regulatory profile for Строфантин К (k-Strophanthin) focuses on documented pharmacokinetic and pharmacodynamic interactions that define constraints for co-administration. These interactions primarily affect drug exposure, clearance, and myocardial activity, and are consistently noted across authoritative government health agencies for the cardiac glycoside class.

---

Pharmacokinetic and Exposure Modification

Co-administration with P-glycoprotein (P-gp) Inhibitors (e.g., Quinidine, Amiodarone) is documented to increase plasma concentration of Строфантин К by inhibiting clearance. Conversely, agents that induce metabolism or P-gp (e.g., Rifampin, St. John's Wort) are officially noted to decrease systemic exposure, which may reduce expected efficacy. These changes mandate regulatory constraints against accumulation or sub-therapeutic levels.

---

Pharmacodynamic and Cardiotoxicity Risk

Interacting Product Category	Regulatory Statement
Potassium-Depleting Drugs (Diuretics, Corticosteroids)	Officially cited to cause hypokalemia, a condition that enhances cardiotoxicity and significantly increases the risk of severe arrhythmias.
Other Antiarrhythmic Agents (Beta-blockers, Verapamil)	Documented to have additive effects on cardiac conduction, increasing the risk of severe bradycardia and heart block.
Intravenous Calcium Salts	Formally documented to increase the risk of serious arrhythmias when used concurrently.

---

Population-Specific Note: Renal impairment is noted in official documentation as a condition that increases the risk of interaction-mediated accumulation due to reduced drug clearance.

Modulation of Ion Transport Pathways

Strophanthin K, a cardiac glycoside, primarily acts by specifically inhibiting the Na^+/ K^+-ATPase (sodium-potassium pump) enzyme on cardiac muscle cell membranes. This enzyme-mediated action disrupts the transport of ions, reducing potassium influx and sodium efflux, which is the foundational molecular step of its mechanism.

Intracellular Calcium Flux

The initial inhibition of the Na^+/ K^+-ATPase leads to an accumulation of intracellular sodium ( Na^+). This rise subsequently impairs the function of the sodium-calcium exchanger ( Na^+/ Ca^2+-exchanger, NCX), reducing the removal of Ca^2+ from the cell. The resulting concentration modulates the interaction with contractile proteins.

Regulation of Myocardial Function

The elevated intracellular Ca^2+ concentration increases the amount of calcium available to interact with contractile proteins (actin and myosin). This engagement enhances the force and speed of myocardial contraction, a predictable physiological adjustment known as a positive inotropic effect, resulting in an augmented force of myocardial contraction. The drug also influences the electrophysiological properties of the heart by prolonging the refractory period of the atrioventricular (AV) node.

Строфантин К is used according to a detailed protocol that strictly defines its administration, dosage, and scheduling. The medicine is formulated as a solution for injection, and the primary route of administration is Intravenous (IV) injection or infusion.

The standard instructions mandate a two-phase dosing strategy: an initial Saturation (Loading) Phase followed by a Maintenance Phase.

---

Administration Parameter	Official Instruction
Route and Rate	IV injection must be administered slowly over a duration of 5–6 minutes; the IV Drip (Infusion) method is also approved.
Preparation	The solution must be diluted prior to use in 10–20 ml of 0.9% Sodium Chloride or 5% Dextrose solution.
Adult Dose Limits	Maximum Single Dose: 0.25 mg. Maximum Daily Dose: 1.0 mg.
Dosing Schedule	The saturation phase typically involves a dose of 0.25 mg administered twice daily, with a 12-hour interval. Maintenance use typically does not exceed 0.25 mg once daily.
Pediatric Rules	Dosing is calculated based on body weight (mg/kg) for children. The maintenance dose is 1/2 to 1/3 of the calculated saturation dose.

---

This protocol strictly defines the procedural sequence for administration. The solution must first undergo the mandatory dilution step before being delivered via the IV route. The precise scheduling of the saturation phase (e.g., 12-hour intervals) and the strict adherence to the maximum dose of 1.0 mg per day govern the intensive initial use, which is then followed by the less frequent maintenance phase for sustained control. This structured approach establishes the standardized use of the medicine.

Research Evidence / Overview of Studies for Строфантин К

Evidence for use in Heart Failure (Chronic Cardiac Insufficiency)

The clinical evaluation of Строфантин К primarily involves studies that was evaluated in adult patients with conditions marked by functional limitations. Research describes that the available evidence includes double-blind crossover Randomized Controlled Trials (RCTs) and other clinical trials. These studies explored how symptoms change over time and measured outcomes related to daily functioning, such as the ability to utilize oxygen during exercise, and assessed the heart's pumping efficiency at rest. The findings describe patterns observed in specific, small populations, such as those with advanced heart failure related to dilated cardiomyopathy.

Key Limitations and Research Uncertainty

What remains uncertain is the current standing of this evidence. The supporting research, while including robust designs such as RCTs, is generally decades old, and comparative evidence is lacking against contemporary treatment protocols. The follow-up durations were limited, meaning long-term outcomes beyond a few months are not well characterized. Furthermore, the studies provided limited information regarding major contemporary endpoints, such as long-term survival rates.

Evidence for use in Specific Arrhythmias, such as atrial fibrillation, is largely derived from pharmacological research and clinical observations. Research examined heart rate and outcomes related to rhythm stability in contexts involving fluctuating or unstable symptoms. This evidence is limited and heterogeneous, and certainty remains low regarding many contemporary questions. The available evidence contributes to the broader evidence landscape but has significant limitations regarding its applicability in current clinical practice settings.

Common questions about Строфантин К (FAQ)

---

Q: What dosage of Strophanthin K is considered safe for most patients?

Official product information establishes strict dosage limits for Strophanthin K. These regulatory limits govern the administration of the medicine, defining a maximum single dose and a maximum daily dose that should not be exceeded.

The purpose of these limits is to regulate the use of the medicine and manage the risks associated with its potency.

---

Q: What does 'narrow therapeutic index' mean for Strophanthin K?

The official instructions emphasize careful dosage because Strophanthin K is considered to have a narrow therapeutic window.

This means there is a small difference between the dose that provides a therapeutic effect and the dose that may cause adverse effects. Strict adherence to the regulatory limits is necessary for the medicine's use to align with official safety protocols.

---

Q: How does Strophanthin K affect heart rate?

Official documents indicate that Strophanthin K can influence the heart’s rhythm. Possible effects mentioned include bradycardia (a slower-than-normal heart rate) and tachycardia (a faster-than-normal heart rate).

These rhythm changes are listed as possible side effects.

---

Q: Why is potassium control so important when using Strophanthin K?

Hypokalemia (low potassium levels) is listed in the official prescribing information as a contraindication for the use of this medicine.

Low potassium is specifically noted as a factor that may increase the drug's toxicity, which is associated with an elevated risk of adverse effects.

---

Q: Is Strophanthin K a medicine for treating the heart?

Strophanthin K is classified as a cardiac glycoside. Official regulatory information states that the medicine is indicated for the treatment of certain established heart conditions.

These conditions include acute and chronic heart failure (stages II–III) and some types of supraventricular arrhythmias (abnormal heart rhythms).

---

Q: Can Strophanthin K be used for the prevention of heart diseases?

The official indications for Strophanthin K describe its use for the treatment of established conditions, such as heart failure and specific types of cardiac arrhythmia.

The regulatory documents do not include indications for the prevention of heart diseases.

---

Q: How soon after Strophanthin K is administered can one feel the effect?

Strophanthin K is administered via the intravenous (IV) route, either by slow injection or infusion.

This method of administration is described in official sources as providing a rapid onset of action for the medicine, meaning the effects begin relatively quickly after the injection or infusion is started.

---

Q: How long does Strophanthin K stay in the body after injection?

Official pharmacokinetic information describes how the body processes the medicine. It states that Strophanthin K is not metabolized (broken down) by the liver.

Instead, it is primarily excreted by the kidneys in its unchanged form.

---

Q: How long does the course of treatment with Strophanthin K usually last?

The official dosing protocol specifies two phases of use: a saturation phase (usually lasting about two days) and a maintenance phase.

The total duration of the treatment course is established by regulatory protocols and varies based on the specific condition being treated.

---

Q: What unusual sensations might occur after Strophanthin K is administered?

Possible side effects listed in official documents include nervous system effects such as headache, dizziness, and sleep disturbances.

Rarely, patients may also experience visual disturbances, such as seeing objects with an unusual yellowish-green tinge.

---

Q: Is it true that Strophanthin K can cause heart rhythm disturbances?

Yes, the official prescribing information lists various types of cardiac rhythm disturbances, including arrhythmia, bradycardia, and tachycardia.

These disturbances are noted as possible side effects.

---

Q: Can Strophanthin K cause nausea or vomiting?

Yes, the official product information lists effects on the digestive system as possible side effects. These include loss of appetite, nausea, and vomiting.

---

Q: Can the medicine affect mood or sleep?

Official documents detail potential side effects related to the nervous system. These include sleep disturbances.

Though rare, central nervous system effects such as depression or psychosis have also been noted.

---

Q: What is glycoside intoxication and how is it related to Strophanthin K?

Glycoside intoxication is the term used to describe a condition of overdosage or toxicity from cardiac glycosides like Strophanthin K.

Regulatory information states this condition may lead to severe cardiac rhythm disturbances (arrhythmias) as well as non-cardiac symptoms like nausea, vomiting, and visual changes.

---

Q: Can one consume alcohol during treatment with Strophanthin K?

Official regulatory sources advise caution regarding alcohol consumption.

It is noted that combining alcohol with Strophanthin K may increase the medicine's toxicity and potentially heighten the occurrence of unwanted side effects.

---

Q: Can one drive a car after Strophanthin K is administered?

The official instructions recommend that patients refrain from driving or operating other mechanisms after administration.

This recommendation is made due to the potential for side effects, such as dizziness or visual disturbances, that could affect concentration.

---

Q: Can Strophanthin K affect the function of the kidneys or liver?

Regulatory information on the drug’s processing by the body (pharmacokinetics) indicates that the medicine is primarily eliminated by the kidneys in its unchanged form.

Therefore, the use of Strophanthin K requires careful consideration of a patient’s kidney function.

---

Q: Are there age restrictions for the use of Strophanthin K?

Official documents include a protocol for pediatric use. The medicine may be used in children, including infants from birth, under strict conditions.

Dosing for pediatric patients is calculated specifically based on body weight.

---

Q: Can Strophanthin K be used during pregnancy or breastfeeding?

The official prescribing information states that the use of Strophanthin K is contraindicated (not permitted) during both pregnancy and breastfeeding.

This restriction is based on the lack of sufficient safety data for the use of the medicine in these populations.

---

Q: For which heart diseases is Strophanthin K strictly contraindicated?

The official prescribing information lists a number of heart conditions that are strict contraindications for the use of Strophanthin K.

These include acute myocardial infarction (heart attack), severe bradycardia (very slow heart rate), and AV block of the II-III degree.

---

Q: Why is an ECG required before prescribing Strophanthin K?

The official instructions mandate that treatment must be carried out under constant ECG (electrocardiography) monitoring.

This monitoring allows for the timely identification of changes in the heart's electrical activity or rhythm that may be associated with the drug’s effects or toxicity.

---

Q: Does the use of Strophanthin K require continuous monitoring by a doctor?

Official regulatory documents clearly state that the use of this medicine requires constant medical supervision.

This is coupled with the requirement for continuous ECG monitoring to manage the risks associated with the drug.

---

Q: What happens if the medicine is accidentally injected too quickly?

The official administration protocol stresses the need for slow intravenous injection over several minutes.

Rapid injection is warned against in regulatory sources as it is associated with the development of cardiac rhythm disturbances, including the risk of cardiac arrest.

---

Q: Can unused ampoules of Strophanthin K be stored at home?

Official storage instructions specify that the medicine must be kept in a location inaccessible to children and protected from light, at a specific temperature.

Following these guidelines helps ensure the drug’s effectiveness and stability are maintained.

---

Q: What medicines are strictly forbidden to take with Strophanthin K?

Regulatory documents address the issue of incompatibilities with other substances. Strophanthin K should not be mixed with certain solutions (e.g., Sodium Bicarbonate solutions) during administration.

They also list other medications with which significant drug-drug interactions may occur.

---

Q: Is the use of Strophanthin K associated with the risk of developing blood clots?

In the list of possible adverse effects, the official documents mention rare disorders of the blood system.

These include thrombocytopenia (low platelet count) and thrombocytopenic purpura.

---

Q: In what cases can Strophanthin K be fatally dangerous?

Official safety warnings highlight two main risks for potentially fatal consequences: severe glycoside intoxication (overdose) and rapid intravenous administration.

Both of these situations carry a significant risk of severe cardiac rhythm disturbances, which can lead to cardiac arrest.

How to Store and Dispose of Строфантин К

The storage and disposal of Строфантин К (Strophanthin K) are governed by official regulatory instructions to maintain product integrity and ensure public safety.

Storage and Protection

Requirement	Official Instruction
Temperature	Store at controlled room temperature, typically not exceeding 25 C or 30 C, as specified on the label.
Light/Container	Keep the ampoules in the original outer carton to protect the medicine from light and moisture.
Safety	Keep Строфантин К out of the sight and reach of children.
Handling	Do not freeze the injectable solution.

Disposal

Expired or unused Строфантин К must be managed as pharmaceutical waste. Do not dispose of the medicine in household trash or flush it down the toilet or drain. Return any unused or expired product to a designated pharmacy or pharmaceutical take-back program for proper disposal, in accordance with local environmental regulations.